First-aid treatment of anaphylaxis to food: Focus on epinephrine

  • F.Estelle R Simons
    Reprint requests: F. Estelle R. Simons, MD, FRCPC, Children's Hospital of Winnipeg, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9
    From the Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health; and the Department of Immunology, National Training Program in Asthma and Allergy, University of Manitoba, Winnipeg, Manitoba, Canada
    Search for articles by this author


      Avoiding food triggers for anaphylactic reactions (severe acute systemic allergic reactions) is easier said than done. Most episodes of anaphylaxis to food occur unexpectedly in the community in the absence of a health care professional. All individuals at risk should therefore have an emergency action plan in place. The cornerstone of first-aid treatment of anaphylaxis is epinephrine injected intramuscularly in the vastus lateralis muscle (lateral aspect of the thigh). In this review, we focus on epinephrine. We examine a therapeutic dilemma: the issue of epinephrine dose selection in an individual for whom no optimal fixed-dose auto-injector formulation exists, and a therapeutic controversy: the issue of epinephrine injection versus an oral H1-antihistamine in anaphylaxis episodes that appear to be mild. The pharmaceutical industry could address the first of these issues by providing a wider range of epinephrine fixed doses in easy-to-use auto-injectors, or by providing adjustable epinephrine doses in auto-injectors. The second issue could be addressed in part by development of alternative routes of epinephrine administration for the first-aid, out-of-hospital treatment of anaphylaxis.



      tmax (Time to peak plasma concentration)
      To read this article in full you will need to make a payment


      Subscribe to Journal of Allergy and Clinical Immunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • James Jr., L.P
        • Austen K.F
        Fatal systemic anaphylaxis in man.
        N Engl J Med. 1964; 270: 597-603
        • Yocum M.W
        • Butterfield J.H
        • Klein J.S
        • Volcheck G.W
        • Schroeder D.R
        • Silverstein M.D
        Epidemiology of anaphylaxis in Olmsted County: a population-based study.
        J Allergy Clin Immunol. 1999; 104: 452-456
        • Simons F.E.R
        • Chad Z.H
        • Gold M
        Anaphylaxis in children: real-time reporting from a national network.
        Int Immunol. 2003; (In press)
        • American Academy of Allergy Asthma and Immunology Board of Directors
        Anaphylaxis in schools and other child-care settings.
        J Allergy Clin Immunol. 1998; 102: 173-176
        • Ewan P.W
        • Clark A.T
        Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan.
        Lancet. 2001; 357: 111-115
        • Sampson H.A
        Anaphylaxis and emergency treatment.
        Pediatrics. 2003; 111: 1601-1608
        • Simons F.E.R
        Epinephrine (adrenaline) in the first-aid, out-of-hospital treatment of anaphylaxis.
        in: Galli S Anaphylaxis. Wiley, Chichester, UK2004: 228-247
        • McLean-Tooke A.P.C
        • Bethune C.A
        • Fay A.C
        • Spickett G.P
        Adrenaline in the treatment of anaphylaxis: what is the evidence?.
        BMJ. 2003; 327: 1332-1335
        • Lieberman P
        Use of epinephrine in the treatment of anaphylaxis.
        Curr Opin Allergy Clin Immunol. 2003; 3: 313-318
        • Hoffman B.B
        Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists.
        in: Hardman J.G Limbird L.E Gilman A.G Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. McGraw-Hill Co, New York2001: 215-268
        • Bautista E
        • Simons F.E.R
        • Simons K.J
        • Becker A.B
        • Duke K
        • Tillett M
        • et al.
        Epinephrine fails to hasten hemodynamic recovery in fully-developed anaphylactic shock.
        Int Arch Allergy Immunol. 2002; 128: 151-164
      1. The online home of the PDR.
        Thomson Healthcare, Montvale (NJ)2003-2004 (Available from) (Accessed February 24, 2004)
        • Simons F.E.R
        • Gu X
        • Silver N.A
        • Simons K.J
        EpiPen Jr versus EpiPen in young children weighing 15-30 kg at risk for anaphylaxis.
        J Allergy Clin Immunol. 2002; 109: 171-175
        • Simons F.E.R
        • Roberts J.R
        • Gu X
        • Simons K.J
        Epinephrine absorption in children with a history of anaphylaxis.
        J Allergy Clin Immunol. 1998; 101: 33-37
        • Simons F.E.R
        • Gu X
        • Simons K.J
        Epinephrine absorption in adults: intramuscular versus subcutaneous injection.
        J Allergy Clin Immunol. 2001; 108: 871-873
        • Sicherer S.H
        • Forman J.A
        • Noone S.A
        Use assessment of self-administered epinephrine among food-allergic children and pediatricians.
        Pediatrics. 2000; 105: 359-362
        • Simons F.E.R
        • Gu X
        • Johnston L
        • Simons K.J
        Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis?.
        Pediatrics. 2000; 106: 1040-1044
        • Simons F.E.R
        • Chan E.S
        • Gu X
        • Simons K.J
        Epinephrine for the out-of-hospital (first aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical?.
        J Allergy Clin Immunol. 2001; 108: 1040-1044
        • Simons F.E.R
        • Gu X
        • Simons K.J
        Outdated EpiPen and EpiPen Jr auto-injectors: past their prime?.
        J Allergy Clin Immunol. 2000; 105: 1025-1030
        • Luciuk G.H
        Adrenalin anaphylaxis.
        J Allergy Clin Immunol. 1993; 91: 153
      2. Fastjekt product information: emergency treatment. 2004 Available from Accessed January 15, 2004.

        • Simons F.E.R
        • Peterson S
        • Black C.D
        Epinephrine dispensing for the out-of-hospital treatment of anaphylaxis in infants and children: a population-based study.
        Ann Allergy Asthma Immunol. 2001; 86: 622-626
        • Chowdhury B.A
        • Meyer R.J
        Intramuscular versus subcutaneous injection of epinephrine in the treatment of anaphylaxis.
        J Allergy Clin Immunol. 2002; 109: 720
        • Simons F.E.R
        • Peterson S
        • Black C.D
        Epinephrine dispensing patterns for an out-of-hospital population: a novel approach to studying the epidemiology of anaphylaxis.
        J Allergy Clin Immunol. 2002; 110: 647-651
        • Pumphrey R.S.H
        Lessons for management of anaphylaxis from a study of fatal reactions.
        Clin Exp Allergy. 2000; 30: 1144-1150
        • Yunginger J.W
        • Sweeney K.G
        • Sturner W.Q
        • Giannandrea L.A
        • Teigland J.D
        • Bray M
        • et al.
        Fatal food-induced anaphylaxis.
        JAMA. 1988; 260: 1450-1452
        • Sampson H.A
        • Mendelson L
        • Rosen J.P
        Fatal and near-fatal anaphylactic reactions to food in children and adolescents.
        N Engl J Med. 1992; 327: 380-384
        • Bock S.A
        • Munoz-Furlong A
        • Sampson H.A
        Fatalities due to anaphylactic reactions to foods.
        J Allergy Clin Immunol. 2001; 107: 191-193
        • Hourihane J.O
        • Kilburn S.A
        • Dean P
        • Warner J.O
        Clinical characteristics of peanut allergy.
        Clin Exp Allergy. 1997; 27: 634-639
        • Gu X
        • Simons K.J
        • Simons F.E.R
        Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? a proof-of-concept study.
        Biopharm Drug Dispos. 2002; 23: 213-216
        • Pumphrey R.S.H
        Fatal posture in anaphylactic shock.
        J Allergy Clin Immunol. 2003; 112: 451-452
        • Simons F.E.R
        in: Adkinson Jr., N.F Yunginger J.W Busse W.W Bochner B.S Holgate S.T Simons F.E.R Middleton's allergy: principles and practice. 6th ed. Mosby, St. Louis, MO2003: 834-869
        • Sicherer S.H
        • Furlong T.J
        • Munoz-Furlong A
        • Burks A.W
        • Sampson H.A
        A voluntary registry for peanut and tree nut allergy: characteristics of the first 5149 registrants.
        J Allergy Clin Immunol. 2001; 108: 128-132
        • Vander Leek T.K
        • Liu A.H
        • Stefanski K
        • Blacker B
        • Bock S.A
        The natural history of peanut allergy in young children and its association with serum peanut-specific IgE.
        J Pediatr. 2000; 137: 749-755
        • Vadas P
        • Perelman B
        Activated charcoal forms non-IgE binding complexes with peanut proteins.
        J Allergy Clin Immunol. 2003; 112: 175-179
        • American Academy of Pediatrics Committee on Injury Violence and Poison Prevention
        Poison treatment in the home.
        Pediatrics. 2003; 112: 1182-1185
        • Leung D.Y.M
        • Sampson H.A
        • Yunginger J.W
        • Burks Jr., A.W
        • Schneider L.C
        • Wortel C.H
        • et al.
        Effect of anti-IgE therapy in patients with peanut allergy.
        N Engl J Med. 2003; 348: 986-993

      Linked Article

      • Correction
        Journal of Allergy and Clinical ImmunologyVol. 113Issue 6
        • Preview
          With regard to the May 2004 article entitled “First-aid treatment of anaphylaxis to food: Focus on epinephrine” (2004;113:837-44): A serious dosage error appears in the section entitled “Epinephrine in the first-aid treatment of anaphylaxis.” On page 837, in the fifth line of the subsection entitled “Evidence base for epinephrine use in anaphylaxis,” the epinephrine dosage for children appears incorrectly as “a maximum of 0.3 mg/kg.” The correct maximum initial dose is 0.2 mg to 0.5 mg in adults; 0.01 mg/kg to a maximum of 0.3 mg in children.
        • Full-Text
        • PDF